University Hospitals of Verona receive green light as part of the RECOVERY study

Last week, the University Hospitals of Verona received the go-ahead to participate in the new baloxavir arm of the ECRAID-coordinated RECOVERY study.

RECOVERY, sponsored by the University of Oxford, is an international adaptive platform trial identifying treatments that may be beneficial for people hospitalised with pneumonia.

RECOVERY started in the UK in early 2020 as the Randomised Evaluation of COVID-19 Therapy, a clinical trial testing treatments for people admitted to hospital with COVID-19 pneumonia. Since then, it has identified five life-saving treatments for COVID-19, and shown that several other commonly used treatments were not effective. RECOVERY is now open at sites across Europe, Asia, and Africa, and in 2023 expanded to test treatments for other types of pneumonia, including influenza and non-viral community-acquired pneumonia.

The University Hospitals of Verona were already participating in two arms of the study, but now, patients with pneumonia caused by influenza can be randomised in three arms: oseltamivir (an antiviral treatment), baloxavir (an antiviral treatment), and corticosteroids, whilst patients with pneumonia caused by other organisms (often referred to as 'community-acquired pneumonia' or CAP) are currently being treated with corticosteroids.

Find out more about RECOVERY here: https://www.recoverytrial.net/